Genomic stratification based on radiosensitivity and PD-L1 for tailoring therapeutic strategies in cervical cancer.

We performed an immunogenomic analysis to help identify a model for the cervical cancer therapeutic module. Patients were divided into groups according to radiosensitivity and PD-L1 expression status. The PD-L1-low-radioresistant (RR) group indicated worse overall survival under radiotherapy. In addition, the PD-L1-low-RR group showed the lowest immunophenoscore and predicted poor response to anti-PD-1 treatment. Differentially expressed genes associated with the PD-L1-low-RR group were found to play a role in the immune response pathways. FGF19 and PLA2G5 were validated to be upregulated in the PD-L1-low-RR group in the Gene Expression Omnibus database, which predicted the overall survival in the The Cancer Genome Atlas. It will be important to test radiosensitivity and PD-L1 stratification to predict the response to strategies in cervical cancer patients.